annual EBITDA:
-$492.89M-$312.91M(-173.87%)Summary
- As of today (September 10, 2025), DNLI annual EBITDA is -$492.89 million, with the most recent change of -$312.91 million (-173.87%) on December 31, 2024.
- During the last 3 years, DNLI annual EBITDA has fallen by -$205.73 million (-71.64%).
- DNLI annual EBITDA is now -791.78% below its all-time high of $71.25 million, reached on December 31, 2020.
Performance
DNLI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$131.92M+$11.34M(+7.91%)Summary
- As of today (September 10, 2025), DNLI quarterly EBITDA is -$131.92 million, with the most recent change of +$11.34 million (+7.91%) on June 30, 2025.
- Over the past year, DNLI quarterly EBITDA has dropped by -$17.27 million (-15.06%).
- DNLI quarterly EBITDA is now -153.73% below its all-time high of $245.51 million, reached on December 31, 2020.
Performance
DNLI quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$524.51M-$17.27M(-3.40%)Summary
- As of today (September 10, 2025), DNLI TTM EBITDA is -$524.51 million, with the most recent change of -$17.27 million (-3.40%) on June 30, 2025.
- Over the past year, DNLI TTM EBITDA has dropped by -$37.80 million (-7.77%).
- DNLI TTM EBITDA is now -850.73% below its all-time high of $69.87 million, reached on December 31, 2020.
Performance
DNLI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
DNLI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -173.9% | -15.1% | -7.8% |
| 3 y3 years | -71.6% | -119.2% | -83.8% |
| 5 y5 years | -140.2% | -123.1% | -137.4% |
DNLI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -173.9% | at low | -176.8% | +7.9% | -254.1% | at low |
| 5 y | 5-year | -791.8% | at low | -153.7% | +7.9% | -850.7% | at low |
| alltime | all time | -791.8% | at low | -153.7% | +7.9% | -850.7% | at low |
DNLI EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$131.92M(-7.9%) | -$524.51M(+3.4%) |
| Mar 2025 | - | -$143.25M(+11.9%) | -$507.25M(+2.7%) |
| Dec 2024 | -$492.89M(+173.9%) | -$127.99M(+5.5%) | -$494.08M(-0.5%) |
| Sep 2024 | - | -$121.35M(+5.8%) | -$496.49M(+2.0%) |
| Jun 2024 | - | -$114.65M(-11.9%) | -$486.71M(+143.1%) |
| Mar 2024 | - | -$130.09M(-0.2%) | -$200.22M(+10.1%) |
| Dec 2023 | -$179.97M(-45.5%) | -$130.40M(+16.9%) | -$181.78M(+18.4%) |
| Sep 2023 | - | -$111.58M(-164.9%) | -$153.50M(+3.6%) |
| Jun 2023 | - | $171.84M(-253.9%) | -$148.13M(-61.0%) |
| Mar 2023 | - | -$111.64M(+9.3%) | -$380.15M(+13.9%) |
| Dec 2022 | -$330.36M(+15.0%) | -$102.12M(-3.9%) | -$333.71M(+8.6%) |
| Sep 2022 | - | -$106.21M(+76.5%) | -$307.41M(+7.7%) |
| Jun 2022 | - | -$60.18M(-7.7%) | -$285.38M(-0.1%) |
| Mar 2022 | - | -$65.20M(-14.0%) | -$285.54M(-1.6%) |
| Dec 2021 | -$287.16M | -$75.81M(-10.0%) | -$290.14M(-1030.7%) |
| Sep 2021 | - | -$84.19M(+39.5%) | $31.18M(-45.0%) |
| Jun 2021 | - | -$60.34M(-13.6%) | $56.71M(-2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$69.80M(-128.4%) | $57.92M(-17.1%) |
| Dec 2020 | $71.25M(-134.7%) | $245.51M(-518.6%) | $69.87M(-130.2%) |
| Sep 2020 | - | -$58.65M(-0.8%) | -$231.34M(+4.7%) |
| Jun 2020 | - | -$59.13M(+2.2%) | -$220.96M(-0.1%) |
| Mar 2020 | - | -$57.86M(+3.9%) | -$221.15M(+8.7%) |
| Dec 2019 | -$205.19M(+426.7%) | -$55.70M(+15.4%) | -$203.39M(+188.1%) |
| Sep 2019 | - | -$48.27M(-18.6%) | -$70.59M(+21.8%) |
| Jun 2019 | - | -$59.32M(+47.9%) | -$57.96M(+24.3%) |
| Mar 2019 | - | -$40.10M(-152.0%) | -$46.63M(+48.4%) |
| Dec 2018 | -$38.96M(-55.3%) | $77.10M(-316.4%) | -$31.41M(-76.1%) |
| Sep 2018 | - | -$35.64M(-25.7%) | -$131.25M(+12.1%) |
| Jun 2018 | - | -$47.98M(+92.8%) | -$117.12M(+69.4%) |
| Mar 2018 | - | -$24.89M(+9.5%) | -$69.14M(+56.3%) |
| Dec 2017 | -$87.06M(+1.3%) | -$22.73M(+5.7%) | -$44.24M(+9.0%) |
| Sep 2017 | - | -$21.51M(+12.7%) | -$40.60M(-18.2%) |
| Dec 2016 | -$85.96M(+419.2%) | -$19.09M(-37.5%) | -$49.62M(+62.5%) |
| Sep 2016 | - | -$30.53M | -$30.53M |
| Dec 2015 | -$16.56M | - | - |
FAQ
- What is Denali Therapeutics Inc. annual EBITDA?
- What is the all time high annual EBITDA for Denali Therapeutics Inc.?
- What is Denali Therapeutics Inc. annual EBITDA year-on-year change?
- What is Denali Therapeutics Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Denali Therapeutics Inc.?
- What is Denali Therapeutics Inc. quarterly EBITDA year-on-year change?
- What is Denali Therapeutics Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Denali Therapeutics Inc.?
- What is Denali Therapeutics Inc. TTM EBITDA year-on-year change?
What is Denali Therapeutics Inc. annual EBITDA?
The current annual EBITDA of DNLI is -$492.89M
What is the all time high annual EBITDA for Denali Therapeutics Inc.?
Denali Therapeutics Inc. all-time high annual EBITDA is $71.25M
What is Denali Therapeutics Inc. annual EBITDA year-on-year change?
Over the past year, DNLI annual EBITDA has changed by -$312.91M (-173.87%)
What is Denali Therapeutics Inc. quarterly EBITDA?
The current quarterly EBITDA of DNLI is -$131.92M
What is the all time high quarterly EBITDA for Denali Therapeutics Inc.?
Denali Therapeutics Inc. all-time high quarterly EBITDA is $245.51M
What is Denali Therapeutics Inc. quarterly EBITDA year-on-year change?
Over the past year, DNLI quarterly EBITDA has changed by -$17.27M (-15.06%)
What is Denali Therapeutics Inc. TTM EBITDA?
The current TTM EBITDA of DNLI is -$524.51M
What is the all time high TTM EBITDA for Denali Therapeutics Inc.?
Denali Therapeutics Inc. all-time high TTM EBITDA is $69.87M
What is Denali Therapeutics Inc. TTM EBITDA year-on-year change?
Over the past year, DNLI TTM EBITDA has changed by -$37.80M (-7.77%)